QWM
NBIX icon

Quaker Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Quaker Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$527 Hold
4
– – ﹤0.01% 688
2025
Q4 		$568 Hold
4
– – ﹤0.01% 666
2025
Q3 		$562 Hold
4
– – ﹤0.01% 577
2025
Q2 		$503 Buy
+4
New +$459 ﹤0.01% 613

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Quaker Wealth Management's NBIX Position: Q1 2026 in Review

Quaker Wealth Management held its Neurocrine Biosciences (NBIX) position steady in Q1 2026 at 4 shares worth $527. The position accounts for ﹤0.01% of the portfolio, ranked #688.

Quaker Wealth Management first reported a position in NBIX in Q2 2025 and has held it in 4 quarters since. The position peaked at $568 in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Quaker Wealth Management held 4 shares of Neurocrine Biosciences worth $527 as of Q1 2026.
  • Quaker Wealth Management left its Neurocrine Biosciences share count unchanged in Q1 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Quaker Wealth Management's portfolio in Q1 2026, its #688 holding.
  • Quaker Wealth Management first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Quaker Wealth Management's Neurocrine Biosciences position peaked at $568 in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Quaker Wealth Management's 13F filing for Q1 2026, filed 10 Apr 2026.